Tactile Acuity in Experimentally Induced Acute Low Back Pain

July 27, 2017 updated by: Wacław Adamczyk, The Jerzy Kukuczka Academy of Physical Education in Katowice

Lumbar Tactile Acuity in Experimentally Induced Acute Low Back Pain

The purpose of this study is to determine whether experimentally induced acute low back pain might lead to alteration in lumbar tactile acuity measured in region affected by pain compared to pain-free side and pain-free controls.

Study Overview

Status

Completed

Detailed Description

Healthy male participants will be recruited at the Academy of Physical Education in Katowice. Each participant will be assessed only once. All participants will be asked to provide written informed consent for participation prior to the experimental procedure and will be naïve to the experimental hypothesis. The plan for this research project has been previously approved by the local bioethical committee.

Between-subject (real-injection, sham-injection and control group) and within-subject (assessment 1 versus assessment 2 and 3) design will be used for the purpose of this experiment. After the screening procedure and preparation phase, participants will be randomly assigned to one of three groups: control, saline injection or sham-injection. Groups will differ only in terms of the specific manipulation: the experimental group will receive intra-muscular saline injection, the sham-injection group will be stimulated by pinprick sensation produced by a PinPrick device. No manipulation will take place in the control group allowing to control for the learning effect. In fact, participants will be informed that the study includes only two branches so they can be assigned either to the group with pain evoked as a result of an injection or to the control group without any noxious stimuli. Not revealing the sham-injection condition will allow for comparison between nociceptive (injection) and non-nociceptive (sham-injection) condition.

Because no previous studies have investigated tactile acuity changes in acute low back pain, the sample size calculation was based on the data from our own systematic review and meta-analysis (Adamczyk et al., under review) and previous cross-sectional data among healthy controls (Adamczyk et al., 2016). Based on reported mean difference of 9.49mm between chronic low back pain patients and healthy controls and standard deviation of 9.90mm, a total sample size of 57 participants (19 per group) is required to detect a significant effect. Power calculation was performed for specific planned-comparison tests that were described in detailed under 'statistical analysis' section below. Calculation was performed in G*Power (G*Power 3.1.9.2 statistical software) with the alpha level set at =0.05 and 80% power.

Baseline differences in descriptive statistics will be analysed by one-way analysis of variance (ANOVA) with 'group' as the between-subject factor. Further statistical comparisons will be performed using a repeated-measures ANOVA design, with 'group' (real-injection, sham-injection, and control group) as between-subject factor and repeated measures (assessment 1, 2 and 3) as a within-subject factor. In order to test hypothesis on tactile acuity alteration during pain induction, F-tests will be followed by planned comparisons on data from assessment 1 versus assessment 2 in experimental group. To determine whether the magnitude of tactile acuity alteration has differed between the groups, planned comparisons will be performed on the difference in tactile acuity (assessment 1 vs. assessment 2) between real-injection and sham-injection group and between real-injection and control group. Bonferroni correction will be used for multiple planned comparisons. Forward, stepwise multiple regression will be performed to determine the degree to which tactile acuity change is predicted by either pain intensity or the size of its distribution. All the analyses will be conducted using the STATISTICA data analysis software, version 12 (StatSoft Inc., Tulsa, OK, USA). The level of significance will be set at p < 0.05.

Study Type

Interventional

Enrollment (Actual)

57

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Katowice, Poland, 40-065
        • The Jerzy Kukuczka Academy of Physical Education

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Only participants with similar mechanical detection threshold (MDT) on both sides of the spine will be included.

Exclusion Criteria:

  • sex: female
  • age < 18 or > 35 years
  • laterality: left-handed
  • current pain experience
  • episodes of back pain lasting more than 24 hours within the previous one-month period
  • history of chronic pain, i.e. pain lasting more than one-month
  • comorbidities affecting the nervous system
  • cardio-vascular diseases
  • psychiatric illnesses
  • any disease requiring systematic drug consumption.
  • diagnosed hypersensitive reaction to saline solution

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Saline Injection
In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl).
In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
Other Names:
  • Experimental pain
EXPERIMENTAL: Sham Injection
In the sham injection group, a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience.
In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
Other Names:
  • Sham pain
NO_INTERVENTION: Control Group
The control group will not receive any kind of pain or pinprick sensation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lumbar tactile acuity measured by two-point discrimination test (TPD).
Time Frame: Measured an average 3 minutes after manipulation (e.g. saline injection).
Mechanical callipers will be delicately applied to the pre-marked axis until the very first blanching of the skin. Testing will be commenced with 0 mm between the two calliper's tips, and then the distance between them will be gradually increased until participants will able to verbally report that two points had been touched instead of one. Subsequently, the descending sequence will be applied until the perception of the two points disappeared.
Measured an average 3 minutes after manipulation (e.g. saline injection).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain intensity measured behaviourally on a Numerical Rating Scale (NRS).
Time Frame: Pain intensity will be measured just after saline/sham injection and every 30 seconds after this time point up until 12 minutes.
The scale for pain intensity ratings will range from 0 = "no pain" to 10 = "the worst pain imaginable"
Pain intensity will be measured just after saline/sham injection and every 30 seconds after this time point up until 12 minutes.
Distribution of pain measured by estimating the diameter of the circle representing area affected by pain. Greater circle (diameter) will refer to the greater distribution of pain (larger body surface affected).
Time Frame: Pain distribution will be measured just after saline/sham injection and every 30 seconds after this time point up until 12 minutes.
Greater circle (diameter in cm) will refer to the greater distribution of pain (larger body surface affected).
Pain distribution will be measured just after saline/sham injection and every 30 seconds after this time point up until 12 minutes.
Fear of pain measured on a Numerical Rating Scale (NRS).
Time Frame: Fear of pain measured only at baseline
Fear of pain will be rated on a scale ranging from 0 = "not at all" to 10 = "very much".
Fear of pain measured only at baseline
Lumbar tactile acuity measured by point-to-point test (PTP).
Time Frame: PTP measured at baseline (1), an average 3 minutes after manipulation (2) (e.g. saline injection) and 12 minutes after manipulation (3)
To perform PTP, participants will be asked to maintain a pen perpendicularly to the surface around the sacrum. Then, the examiner will lightly touch one of the pre-marked point at the participants' back. The participants will be instructed to touch the point that was stimulated by assessor. To analyse PTP, the distance between pre-marked point and points indicated by the participants will be measured with callipers.
PTP measured at baseline (1), an average 3 minutes after manipulation (2) (e.g. saline injection) and 12 minutes after manipulation (3)
Lumbar tactile acuity measured by two-point estimation test (TPE)
Time Frame: PTP measured at baseline (1), an average 3 minutes after manipulation (2) (e.g. saline injection) and 12 minutes after manipulation (3)
For the two-point estimation test, assessor will apply one tactile stimulus until the very first blanching of the skin, with a 120 mm horizontal separation between the callipers' tips. Subsequently to the tactile stimulation, patients will be asked to manually indicate with their callipers the distance they have perceived (TPE score).
PTP measured at baseline (1), an average 3 minutes after manipulation (2) (e.g. saline injection) and 12 minutes after manipulation (3)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fear of Pain Questionnaire (FPQ-III).
Time Frame: Measured only at baseline
FPQ-III consists of three subscales measuring: minor pain, severe pain, and medical pain. Each subscale contains 10 items. The total score has a range 30-150. A higher score indicates greater fear of pain.
Measured only at baseline
Pain Catastrophizing Scale (PCS).
Time Frame: Measured only at baseline
The PCS scale includes 13 items creating three subscales: magnification, rumination and helplessness. All three scales measure a tendency to exaggerate and misinterpret threatening situations.
Measured only at baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Wacław M Adamczyk, Msc, The Jerzy Kukuczka Academy of Physical Education

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2017

Primary Completion (ACTUAL)

June 1, 2017

Study Completion (ACTUAL)

July 1, 2017

Study Registration Dates

First Submitted

January 9, 2017

First Submitted That Met QC Criteria

January 11, 2017

First Posted (ESTIMATE)

January 13, 2017

Study Record Updates

Last Update Posted (ACTUAL)

July 31, 2017

Last Update Submitted That Met QC Criteria

July 27, 2017

Last Verified

July 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Back Pain

Clinical Trials on Saline injection

3
Subscribe